Related Tags >> FDA AstraZeneca Phase III milestones

Pozen News

Most Popular Pozen Story

AstraZeneca, Pozen start Phase III combo drug trial

September 7, 2007 — 6:59am ET

AstraZeneca and Pozen are starting Phase III trial of PN400, an experimental drug for arthritis pain that combines AstraZeneca's heartburn drug Nexium with the anti-inflammatory drug naproxen. In... Read more...

Pozen Press Releases

POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
POZEN Informed of FDA Internal Review of Gastric Ulcers as a Primary Endpoint in Clinical Trials
PRSS RELEASE: Pozen, AstraZeneca Announce Start of the PN 400 Phase III Program

Latest Headlines

Pozen touts positive data on new arthritis therapy
December 3, 2008
ALSO NOTED: Acadia reports positive psychosis data; Alcon drug gets approval; FDA green lights migraine drug; and much more...
April 16, 2008
AstraZeneca, Pozen start Phase III combo drug trial
September 7, 2007
Pozen shares sink on latest Trexima delay
August 2, 2007
ALSO NOTED: FDA deadline looms for Trexima; Manhattan Pharma discontinues program; and much more...
July 10, 2007
New combos of old drugs may be boon to biotech
July 3, 2007
Pozen shares sink on new demand for data
December 12, 2006
ALSO NOTED: Nucryst drug fails trial; Dr. Bugg to retire from Biocryst; Pozen shares jump; and much more...
September 20, 2006
DEALS: AstraZeneca, Pozen in $375M licensing deal
August 2, 2006
Pozen shares soar on rich pain med deal
August 1, 2006
ALSO NOTED: Occulogix files IDE; North Carolina in running for plant; and much more...
June 11, 2006
FDA decision on Trexima may trigger new studies
June 8, 2006
SPOTLIGHT: FDA greenlights Pozen Phase III
April 20, 2006
ALSO NOTED: Pozen wins UK approval; Genosis raises funds; Eisai transfers drug rights;and much more...
November 27, 2005
C&L: David R. Smith appointed CFO of Galapagos
November 8, 2005
SPOTLIGHT: Pozen to pocket $20M
October 11, 2005
Pozen files NDA for new migraine treatment
August 7, 2005
Pozen loses latest bid for FDA approval of MT100
August 4, 2005
ALSO NOTED: Par drops Advancis partnership; Diovan gets new indication; Pozen makes case for MT-100; and much more...
August 3, 2005

Paid Research Reports

More Research Reports >>